Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | NRAS |
Variant | G12S |
Impact List | missense |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | NRAS G12S is a hotspot mutation that lies within a GTP-binding region of the Nras protein (UniProt.org). G12S results in increased Erk phosphorylation and cell proliferation, is transforming in culture (PMID: 17823240), and is predicted to lead to a loss of Nras protein function based on the effects of HRAS G12S (PMID: 24224811, PMID: 21850009, PMID: 6330729). |
Associated Drug Resistance | |
Category Variants Paths |
NRAS mutant NRAS act mut NRAS G12S NRAS mutant NRAS exon2 NRAS G12X NRAS G12S |
Transcript | NM_002524.5 |
gDNA | chr1:g.114716127C>T |
cDNA | c.34G>A |
Protein | p.G12S |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_002524.4 | chr1:g.114716127C>T | c.34G>A | p.G12S | RefSeq | GRCh38/hg38 |
NM_002524.5 | chr1:g.114716127C>T | c.34G>A | p.G12S | RefSeq | GRCh38/hg38 |
NM_002524 | chr1:g.114716127C>T | c.34G>A | p.G12S | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05638698 | Phase II | Balstilimab + QS21 + TG01 QS21 + TG01 | Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer (TESLA) | Active, not recruiting | USA | 0 |
NCT05726864 | Phase Ib/II | ELI-002 | A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors (AMPLIFY-7P) | Active, not recruiting | USA | 0 |